Hanyu RAO

Email : raohanyu@sjtu.edu.cn

Office address : 106 Med-X Research Institute (Xuhui)

Website : bme.sjtu.edu.cn/Web/FacultyDetail/909


Dr. Hanyu Rao is an Assistant Professor (Research) in School of Biomedical Engineering, Shanghai Jiao Tong University. He obtained B.S. degree in Life Science in 2015 from Hubei University, and Ph.D. degree in Oncology in 2021 from Shanghai Jiao Tong University. Then he joined School of Biomedical Engineering in Shanghai Jiao Tong University and worked as an Assistant Professor (Research) in 2021. He focused on the important role and mechanism of cancer-related genes in tumorigenesis and mesenchymal stem cell carrier cell immunotherapy. In recent years, he has published several papers in mainstream SCI journals in the field of cancer, and has authorized one Chinese invention patent. He has participated in the cooperative research project between Shanghai Jiaotong University and the University of Sydney, and visited the school of Biomedical Engineering, the University of Sydney, Australia in 2019. He has successively participated in 6 scientific research projects, including key projects and general projects of the National Natural Science Foundation of China and Shanghai Science and Technology Commission.

Education background

(1) 2006-2010 Bachelor - Hubei University

(2) 2010-2016 Ph.D. - Shanghai Jiao Tong University

Work Experience

2021-, Assistant ProfessorSchool of Biomedical Engineering (BME)Shanghai Jiao Tong University 

Areas of Research Interests

(1) Functional mechanism of tumor related genes in tumor pathogenesis

(2) Mesenchymal stem cell carrier cell immunotherapy


Research Projects

1. The Mechanism of Setd2 in Suppression of Clear Cell Renal Cell Carcinoma through Lipid Metabolism

2. Immune Factor X and Y Promote the TherapeuticEffect of Mesenchymal Stem Cells in Colorectal Cancer

Selected Publications

1. Rao H, Li X, Liu M, Liu J, Li X, Xu J, Li L, Gao WQ. DIRAS2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein. Oncogene. 2020 May;39(19):3853-3866.
2. Rao H, Li X, Liu M, Liu J, Feng W, Tang H, Xu J, Gao WQ, Li L. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma. Cancer Res. 2021 Jul 1;81(13):3554-3567.
3. Liu M, Rao H, Liu J, Li X, Feng W, Gui L, Tang H, Xu J, Gao WQ, Li L. The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis. Redox Biol. 2021 Jul;43:102004.
4. Li X, Liu C, Zhu Y, Rao H, Liu M, Gui L, Feng W, Tang H, Xu J, Gao WQ, Li L. SETD2 epidermal deficiency promotes cutaneous wound healing via activation of AKT/mTOR Signalling. Cell Prolif. 2021 Jun;54(6):e13045.
5. Liu J, Feng W, Liu M, Rao H, Li X, Teng Y, Yang X, Xu J, Gao W, Li L. Stomach-specific c-Mycoverexpression drives gastric adenoma in mice via AKT/mTOR signaling. Bosn J Basic Med Sci. 2020 Nov